The extracellular matrix is a fundamental, core component of all tissues and organs, and is
essential for the existence of multicellular organisms. From the earliest stages of organism …

T cells genetically engineered to express chimeric antigen receptors (CARs) have proven—
and impressive—therapeutic activity in patients with certain subtypes of B cell leukaemia or …

Chimeric antigen receptor (CAR) T cell therapy has garnered significant excitement due to
its success for hematological malignancies in clinical studies leading to the US Food and …

Unique, functional, homodimeric heavy chain–only antibodies, devoid of light chains, are
circulating in the blood of Camelidae. These antibodies recognize their cognate antigen via …

The development of targeted medicine has greatly expanded treatment options and spurred
new research avenues in cancer therapeutics, with monoclonal antibodies (mAbs) emerging …

A nanobody (Nb) is a registered trademark of Ablynx, referring to the single antigen‐binding
domain of heavy chain‐only antibodies (HCAbs) that are circulating in Camelidae. Nbs are …

Bioorthogonal chemistry is a powerful tool to site-specifically activate drugs in living systems.
Bioorthogonal reactions between a pair of biologically reactive groups can rapidly and …

The efficacy of immunotherapy is limited by the paucity of T cells delivered and infiltrated into
the tumors through aberrant tumor vasculature. Here, we report that phosphoglycerate …

Chimeric antigen receptor (CAR) T cells use re-engineered cell surface receptors to
specifically bind to and lyse oncogenic cells. Two clinically approved CAR-T–cell therapies …

Chimeric antigen receptor T-cell (CAR-T) therapy is the result of combining genetic
engineering-based cancer immunotherapy with adoptive cell therapy (ACT). CAR-T therapy …